As interest in microbiome therapeutics continues to grow, discussions often focus on scientific discoveries, clinical research and emerging treatment approaches. However, one of the most important factors supporting the responsible development of the field is regulation.
From faecal microbiota transplantation (FMT) to next generation microbiome therapeutics, regulatory frameworks play a fundamental role in helping ensure quality, consistency, safety and traceability. Although regulatory approaches differ around the world, they all share a common goal: protecting patients while supporting scientific innovation.
Why does FMT require regulation?
Unlike conventional medicines, FMT involves the transfer of a complex community of living microorganisms from a healthy donor to a recipient. As a human-derived biological material, its manufacture and clinical use require careful oversight to help ensure quality, safety and traceability.
Robust regulation supports every stage of the process, from donor eligibility and laboratory testing to manufacturing, storage and clinical administration. Although the legal frameworks differ between countries, the overarching objective remains the same: protecting patients while enabling access to safe, high-quality therapies.
Regulation in the UK
In the UK, FMT intended for clinical use is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) as a medicinal product.
This means that manufacturers must operate within a regulated framework and hold the appropriate licences for manufacture. FMT products are expected to be produced under stringent quality systems, with comprehensive donor screening, validated manufacturing processes, quality control and full traceability throughout the manufacturing lifecycle.
This regulatory approach reflects the importance of maintaining consistent manufacturing standards for therapies derived from human biological material.
Regulation across Europe
Across Europe, the regulatory landscape is more varied. Individual countries are responsible for regulating FMT within their own healthcare systems, meaning the legal classification and regulatory pathway can differ between Member States.
Despite these differences, there is broad agreement on several core principles. Medical oversight, rigorous donor screening, controlled manufacturing, quality assurance and traceability remain central to clinical practice across Europe.
The European Union’s Substances of Human Origin (SoHO) Regulation also includes human intestinal microbiota within its scope. The regulation aims to strengthen quality and safety standards for substances of human origin while providing a harmonised framework that will be implemented by national authorities.
Regulation in the US
In the United States, the Food and Drug Administration (FDA) oversees faecal microbiota products.The regulatory approach differs from that of the UK.
For patients with recurrent C. difficile infection who have not responded to standard therapies, the FDA exercises enforcement discretion under specific circumstances, allowing access to conventional FMT without requiring an Investigational New Drug (IND) application in certain clinical settings. This policy is subject to defined conditions and does not generally apply to products obtained from stool banks.
Alongside conventional FMT, the United States has also seen the approval of microbiota-based therapeutic products, reflecting the continued evolution of microbiome-based medicine under established regulatory pathways.
Why do regulatory approaches differ?
The differences seen around the world largely reflect how individual healthcare systems have chosen to classify FMT and other microbiome based therapies.
Some countries regulate FMT as a medicinal product, while others apply alternative frameworks for substances of human origin or biological products. Historical clinical practice, national legislation and the pace of scientific development have all influenced these decisions.
Despite these differences, there is growing international recognition of several core principles:
- Comprehensive donor screening and eligibility assessment
- Laboratory testing
- Controlled manufacturing processes
- Quality management systems
- Storage and distribution controls
- Product traceability and documentation
- Clinical oversight and patient safety
These principles provide the foundation for the responsible manufacture and clinical use of FMT regardless of the specific regulatory pathway adopted.
Supporting quality, consistency and traceability
One of the greatest challenges in microbiome therapeutics is biological variability. Unlike many conventional pharmaceuticals, microbiome based therapies contain diverse microbial communities that can naturally vary between individuals.Regulatory frameworks encourage the implementation of validated manufacturing processes, standard operating procedures, quality management systems and predefined release criteria that help support product consistency.
As the field continues to mature, standardisation is becoming increasingly important for both clinical practice and future therapeutic development.Traceability is equally important. From donor screening through to final product release, robust documentation systems help ensure that every stage of the manufacturing process can be tracked, reviewed and verified. This level of oversight supports quality assurance, regulatory compliance and ongoing patient safety throughout the product lifecycle.r paragraph here
Looking Ahead
Microbiome science continues to evolve rapidly, with increasing research into FMT, live biotherapeutic products and other microbiome based therapies. As these technologies advance, regulatory frameworks will continue to develop alongside them.
While countries may adopt different legal approaches, the overall direction is clear. There is increasing international recognition that robust regulation is essential for supporting innovation while maintaining high standards of quality, safety and traceability.
Scientific breakthroughs often attract the headlines, but strong regulatory frameworks provide the foundation for the responsible development, manufacture and clinical use of microbiome therapeutics around the world.
